



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DC-0199
Inventors: Cheung et al.
Serial No.: 10/043,539
Filing Date: January 11, 2002
Examiner: Portner, Virginia Allen
Customer No.: 26259
Group Art Unit: 1645
Confirmation No.: 7285
Title: Compositions and Methods for Affecting
Virulence Determinants in Bacteria

"Express Mail" Label No. EV735453473US
Date of Deposit January 12, 2006

I hereby certify that this paper is being deposited with the
United States Postal Service "Express Mail Post Office
to Addressee" service under 37 CFR 1.10 on the date
indicated above and is addressed to the Mail Stop Fee
Amendment, Commissioner for Patents,
Post Office Box 1450, Alexandria, VA 22313-1450

By (Signature)
Typed Name: Jane Massey Licata, Reg. No. 32,257

Mail Stop Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

- () In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.
- (XX) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
- () Certification in Accordance with §1.97(e) is attached hereto; or
- (XX) Authorization to charge Deposit Account No. 50-1619 the fee of \$180.00 as set forth in §1.17(p) is provided.
- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).
- (XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.


() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,




Jane Massey Licata
Registration No. 32,257

Date: January 12, 2006

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515



Sheet 01 of 01

Form PTO-1449 Modified		Docket No. DC-0199	Serial No. 10/043,539
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Cheung et al.	
		Filing Date January 11, 2002	Group 1645
U.S. Department of Commerce			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	BA	Topham et al., "Prediction of the stability of protein mutants based on structural environment-dependent amino acid substitution and propensity tables", Protein Engineering 1997 10(1):7-21	
	BB	Tretiakova et al., "Rational design of cytotoxic T-cell inhibitors", Nature Biotechnology 2000 18:984-988	
EXAMINER		DATE CONSIDERED	